South Africa Leads World with New HIV Prevention Injection

South Africa is making history by introducing Lenacapavir, a groundbreaking HIV prevention injection that only needs to be taken twice a year instead of daily pills.

The twice-yearly injection represents a massive leap forward in HIV prevention technology. Clinical trials showed unprecedented effectiveness, and now South Africa is leading the world in making it available through its public healthcare system.

This isn't a lucky break. South Africa laid the groundwork for this moment over ten years ago with strategic investments in HIV prevention infrastructure.

Back in 2016, the country took a bold step by introducing daily oral PrEP (pre-exposure prophylaxis) when many nations were still debating whether it was even feasible. By 2021, South Africa had scaled the program across its entire public health sector.

Today, more than 2.2 million South Africans have started oral PrEP through public programs. That massive achievement created the trained workforce, supply chains, and community networks needed to quickly roll out Lenacapavir.

The new injection solves a major challenge with daily prevention methods: remembering to take a pill every single day. For adolescent girls, young women, sex workers, and other vulnerable populations, the twice-yearly option offers convenience and privacy that could dramatically improve protection rates.

Health Minister Dr. Aaron Motsoaledi emphasized that Lenacapavir isn't replacing existing prevention methods. Instead, it's adding another choice so people can pick what works best for their lives and circumstances.

The Ripple Effect

South Africa's approach shows other countries what's possible when governments invest early in prevention infrastructure. The nation integrated HIV prevention into routine primary healthcare alongside sexual and reproductive health services, TB screening, and maternal care.

This comprehensive system meant South Africa could move faster than almost any other country when Lenacapavir became available. While international partners provided early support, the government has committed to long-term domestic financing as more affordable generic versions become available.

The model balances immediate action with sustainable planning. By building strong foundations first, South Africa positioned itself to rapidly adopt breakthrough technologies as they emerge.

Other nations facing high HIV rates are now watching South Africa's rollout closely. The country's success could accelerate global efforts to end new HIV infections by proving that long-acting prevention tools can work at scale in real-world health systems.

South Africa's decade of strategic leadership is now paying off in expanded choices, better access, and renewed hope for ending new infections.